Distinctive impact of pre-existing interstitial lung disease on the risk of chemotherapy-related lung injury in patients with lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 77, Issue 5, 2016, Pages 1031-1038

  Ozawa, Yuichi ^a   Akahori, Daisuke ^a   Koda, Keigo ^a   Abe, Takefumi ^a   Hasegawa, Hirotsugu ^a   Matsui, Takashi ^a   Tanahashi, Masayuki ^a   Niwa, Hiroshi ^a   Yamada, Kazunari ^a   Yokomura, Koshi ^a   Suda, Takafumi ^b  

^a SEIREI MIKATAHARA GENERAL HOSPITAL   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Docetaxel; Interstitial lung disease; Lung cancer; S 1

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; NAVELBINE; PACLITAXEL; PEMETREXED; ANTINEOPLASTIC AGENT; DRUG COMBINATION; OTERACIL; S 1 (COMBINATION); TAXOID; TEGAFUR;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG CANCER; LUNG INJURY; MAJOR CLINICAL STUDY; MALE; PRE EXISTING INTERSTITIAL LUNG DISEASE; PRIORITY JOURNAL; RADIOLOGICAL PROCEDURES; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; RISK FACTOR; CHEMICALLY INDUCED; COMPLICATION; DIAGNOSTIC IMAGING; DRUG COMBINATION; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MEDICAL RECORD; MIDDLE AGED; PREDICTIVE VALUE; RISK; STATISTICAL MODEL; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG COMBINATIONS; FEMALE; HUMANS; LOGISTIC MODELS; LUNG DISEASES, INTERSTITIAL; LUNG INJURY; LUNG NEOPLASMS; MALE; MEDICAL RECORDS; MIDDLE AGED; OXONIC ACID; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK; TAXOIDS; TEGAFUR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84962647748     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-016-3025-7     Document Type: Article

References (29)

1. Wells C, Mannino DM (1996) Pulmonary fibrosis and lung cancer in the United States: analysis of the multiple cause of death mortality data, 1979 through 1991. South Med J 89 (5): 505-510
2. Ozawa Y, Suda T, Naito T, Enomoto N, Hashimoto D, Fujisawa T, Nakamura Y, Inui N, Nakamura H, Chida K (2009) Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology 14 (5): 723-728. doi: 10.1111/j.1440-1843.2009.01547.x
3. Matsushita H, Tanaka S, Saiki Y, Hara M, Nakata K, Tanimura S, Banba J (1995) Lung cancer associated with usual interstitial pneumonia. Pathol Int 45 (12): 925-932
4. Le Jeune I, Gribbin J, West J, Smith C, Cullinan P, Hubbard R (2007) The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir Med 101 (12): 2534-2540. doi: 10.1016/j.rmed.2007.07.012
5. Hubbard R, Venn A, Lewis S, Britton J (2000) Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med 161 (1): 5-8. doi: 10.1164/ajrccm.161.1.9906062
6. Kenmotsu H, Naito T, Mori K, Ko R, Ono A, Wakuda K, Imai H, Taira T, Murakami H, Endo M, Takahashi T (2015) Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease. Cancer Chemother Pharmacol 75 (3): 521-526. doi: 10.1007/s00280-014-2670-y
7. Kenmotsu H, Naito T, Kimura M, Ono A, Shukuya T, Nakamura Y, Tsuya A, Kaira K, Murakami H, Takahashi T, Endo M, Yamamoto N (2011) The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. J Thorac Oncol 6 (7): 1242-1246. doi: 10.1097/JTO.0b013e318216ee6b
8. Isobe K, Hata Y, Sakamoto S, Takai Y, Shibuya K, Homma S (2010) Clinical characteristics of acute respiratory deterioration in pulmonary fibrosis associated with lung cancer following anti-cancer therapy. Respirology 15 (1): 88-92. doi: 10.1111/j.1440-1843.2009.01666.x
9. Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, Tsuboi M, Yokota S, Nakagawa K, Suga M, Jiang H, Itoh Y, Armour A, Watkins C, Higenbottam T, Nyberg F (2008) Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 177 (12): 1348-1357. doi: 10.1164/rccm.200710-1501OC
10. Watanabe N, Niho S, Kirita K, Umemura S, Matsumoto S, Yoh K, Ohmatsu H, Goto K (2015) Second-line docetaxel for patients with platinum-refractory advanced non-small cell lung cancer and interstitial pneumonia. Cancer Chemother Pharmacol 76 (1): 69-74. doi: 10.1007/s00280-015-2775-y
11. Minegishi Y, Sudoh J, Kuribayasi H, Mizutani H, Seike M, Azuma A, Yoshimura A, Kudoh S, Gemma A (2011) The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias. Lung Cancer 71 (1): 70-74. doi: 10.1016/j.lungcan.2010.04.014
12. Kato M, Shukuya T, Takahashi F, Mori K, Suina K, Asao T, Kanemaru R, Honma Y, Muraki K, Sugano K, Shibayama R, Koyama R, Shimada N, Takahashi K (2014) Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease. BMC Cancer 14: 508. doi: 10.1186/1471-2407-14-508
13. Enomoto Y, Inui N, Imokawa S, Karayama M, Hasegawa H, Ozawa Y, Matsui T, Yokomura K, Suda T (2015) Safety of topotecan monotherapy for relapsed small cell lung cancer patients with pre-existing interstitial lung disease. Cancer Chemother Pharmacol 76 (3): 499-505. doi: 10.1007/s00280-015-2816-6
14. Yoh K, Kenmotsu H, Yamaguchi Y, Kubota K, Ohmatsu H, Goto K, Niho S, Ohe Y, Saijo N, Nishiwaki Y (2010) Severe interstitial lung disease associated with amrubicin treatment. J Thorac Oncol 5 (9): 1435-1438. doi: 10.1097/JTO.0b013e3181e369a8
15. Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S, Hasegawa K, Niitani H (2001) Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 85 (7): 939-943. doi: 10.1038/sj.bjc.6692031
16. Kubota K, Sakai H, Katakami N, Nishio M, Inoue A, Okamoto H, Isobe H, Kunitoh H, Takiguchi Y, Kobayashi K, Nakamura Y, Ohmatsu H, Sugawara S, Minato K, Fukuda M, Yokoyama A, Takeuchi M, Michimae H, Gemma A, Kudoh S (2015) A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial. Ann Oncol 26 (7): 1401-1408. doi: 10.1093/annonc/mdv190
17. Ozawa Y, Abe T, Omae M, Matsui T, Kato M, Hasegawa H, Enomoto Y, Ishihara T, Inui N, Yamada K, Yokomura K, Suda T (2015) Impact of Preexisting Interstitial Lung Disease on Acute, Extensive Radiation Pneumonitis: retrospective Analysis of Patients with Lung Cancer. PLoS ONE 10 (10): e0140437. doi: 10.1371/journal.pone.0140437
18. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D (2013) An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188 (6): 733-748. doi: 10.1164/rccm.201308-1483ST
19. Hansell DM, Bankier AA, MacMahon H, McLoud TC, Muller NL, Remy J (2008) Fleischner Society: glossary of terms for thoracic imaging. Radiology 246 (3): 697-722. doi: 10.1148/radiol.2462070712
20. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schunemann HJ (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183 (6): 788-824. doi: 10.1164/rccm.2009-040GL
21. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, KohlhauflM, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crino L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR (2015) Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (17): 1627-1639. doi: 10.1056/NEJMoa1507643
22. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Aren Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR (2015) Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373 (2): 123-135. doi: 10.1056/NEJMoa1504627
23. Kudoh S, Takeda K, Nakagawa K, Takada M, Katakami N, Matsui K, Shinkai T, Sawa T, Goto I, Semba H, Seto T, Ando M, Satoh T, Yoshimura N, Negoro S, Fukuoka M (2006) Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan thoracic oncology group trial (WJTOG 9904). J Clin Oncol 24 (22): 3657-3663. doi: 10.1200/jco.2006.06.1044
24. Okamoto I, Yoshioka H, Morita S, Ando M, Takeda K, Seto T, Yamamoto N, Saka H, Asami K, Hirashima T, Kudoh S, Satouchi M, Ikeda N, Iwamoto Y, Sawa T, Miyazaki M, Tamura K, Kurata T, Fukuoka M, Nakagawa K (2010) Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-smallcell lung cancer: results of a west Japan oncology group study. J Clin Oncol 28 (36): 5240-5246. doi: 10.1200/jco.2010.31.0326
25. Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, Czyzewicz G, Orlov SV, Lewanski CR, Thomas M, Bidoli P, Dakhil S, Gans S, Kim JH, Grigorescu A, Karaseva N, Reck M, Cappuzzo F, Alexandris E, Sashegyi A, Yurasov S, Perol M (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-smallcell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384 (9944): 665-673. doi: 10.1016/s0140-6736(14)60845-x
26. Ryerson CJ, Cottin V, Brown KK, Collard HR (2015) Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm. Eur Respir J 46 (2): 512-520. doi: 10.1183/13993003.00419-2015
27. Ueki N, Matsuo Y, Togashi Y, Kubo T, Shibuya K, Iizuka Y, Mizowaki T, Togashi K, Mishima M, Hiraoka M (2015) Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancer. J Thorac Oncol 10 (1): 116-125. doi: 10.1097/jto.0000000000000359
28. Sugiura H, Takeda A, Hoshi T, Kawabata Y, Sayama K, Jinzaki M, Kuribayashi S (2012) Acute exacerbation of usual interstitial pneumonia after resection of lung cancer. Ann Thorac Surg 93 (3): 937-943. doi: 10.1016/j.athoracsur.2011.12.010
29. Duffy AG, Greten TF (2014) Immunological off-target effects of standard treatments in gastrointestinal cancers. Ann Oncol 25 (1): 24-32. doi: 10.1093/annonc/mdt349